Top Employer-Paid Stories
Regeneron becomes final major pharmaceutical company to join Trump's MFN initiative
By Michael PopkeRegeneron will provide Otarmeni — a new gene therapy for an ultra-rare form of genetic hearing loss recently approved by the U.S. Food and Drug Administration — for free under a new agreement with the U.S. government.





